One of the significant benefits of decitabine is its ability to target and modify epigenetic alterations in cancer cells. This can lead to the reactivation of tumor suppressor genes and a reduction in cancer cell proliferation. For patients with AML and MDS, decitabine has been shown to improve survival rates and quality of life compared to other treatments.
